GSH response copolymers have gained significant attention in the field of drug delivery due to their ability to selectively release drugs in GSH-rich environments, such as tumor cells. This targeted drug delivery approach holds the potential to enhance the therapeutic efficacy of anticancer drugs while minimizing their systemic toxicity. When the GSH response copolymer reaches the target tissue or cell, which is often characterized by higher GSH levels compared to healthy tissue, the presence of GSH triggers the cleavage or disassembly of the copolymer structure. This cleavage event can lead to the release of the encapsulated drug or detachment of the drug from the copolymer backbone, thereby achieving site-specific drug delivery.